FORMULATION AND RELEASE DISTINCTIVENESS OF A NOVEL MODIFIED DRUG DELIVERY DEVICE IN TREATMENT OF HYPERTENSION: LOSARTAN POTASSIUM MATRIX TABLETS

Angiotensin-II receptor blocker losartan, approved by the FDA in 1995, is used to treat hypertension, diabetic nephropathy, and to lower the risk of stroke. A considerable increase in the risks of heart, brain, kidney diseases is caused by hypertension, sometimes known as the "silent killer," which is the first world's largest cause of premature death. Adults in low- and middle-income countries who are between the ages of 30-79 are affected by hypertension, with the number of cases rising from 650 million to 1.28 billion during the past 30 years. Because it could not have any symptoms or warning indications, 46% of adults are unaware of it. Matrix tablets of Losartan potassium as Systems for delivering drugs with a sustained release are intended to prolong the therapeutic effect of a drug after it has been administered in a single dose. Hydrophobic and hydrophilic matrices have been utilized for polymeric matrices in matrix tablets, which regulate the drug's release and have different solubility qualities. Designing and characterizing tablets with a sustained release of losartan potassium are the goals of the current work. Matrix tablets containing 50 mg losartan were developed using 3 different polymers; HPMC-K4, HPMC-K15 &synthetic Ethyl Cellulose (EC) with sodium alginate in different drug polymer ratios (30, 40, 50 mg) respectively. According to the study, the formulation S3 using (HPMC-K4: Sodium alginate as in 50:50 ratio) demonstrated sustained drug release at a rate of 95.1% and displayed the greatest swelling index when compared to other formulations